FDA Inspection 1210971 — Boehringer Ingelheim RCV GmbH & Co KG
The FDA completed an inspection of Boehringer Ingelheim RCV GmbH & Co KG on March 2, 2023 in Vienna. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- March 2, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Vienna (Austria)
Additional Details
Mutual Recognition Agreement (MRA)